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Abstract
Background: The major goal of the study was to compare the genetic programs utilized by the neuropoietic cytokine
Interleukin-6 (IL-6) and the neurotrophin (NT) Nerve Growth Factor (NGF) for neuronal differentiation.
Results: The designer cytokine Hyper-IL-6 in which IL-6 is covalently linked to its soluble receptor s-IL-6R as well as NGF were
used to stimulate PC12 cells for 24 hours. Changes in gene expression levels were monitored using Affymetrix GeneChip
technology. We found different expression for 130 genes in IL-6- and 102 genes in NGF-treated PC12 cells as compared to
unstimulated controls. The gene set shared by both stimuli comprises only 16 genes.
A key step is upregulation of growth factors and functionally related external molecules known to play important roles in
neuronal differentiation. In particular, IL-6 enhances gene expression of regenerating islet-derived 3 alpha (REG3A; 1084-fold),
regenerating islet-derived 3 beta (REG3B/PAPI; 672-fold), growth differentiation factor 15 (GDF15; 80-fold), platelet-derived
growth factor alpha (PDGFA; 69-fold), growth hormone releasing hormone (GHRH; 30-fold), adenylate cyclase activating
polypeptide (PACAP; 20-fold) and hepatocyte growth factor (HGF; 5-fold). NGF recruits GDF15 (131-fold), transforming
growth factor beta 1 (TGFB1; 101-fold) and brain-derived neurotrophic factor (BDNF; 89-fold). Both stimuli activate growth-
associated protein 43 (GAP-43) indicating that PC12 cells undergo substantial neuronal differentiation.
Moreover, IL-6 activates the transcription factors retinoic acid receptor alpha (RARA; 20-fold) and early growth response 1
(Egr1/Zif268; 3-fold) known to play key roles in neuronal differentiation.
Ingenuity biological function analysis revealed that completely different repertoires of molecules are recruited to exert the same
biological functions in neuronal differentiation. Major sub-categories include cellular growth and differentiation, cell migration,
chemotaxis, cell adhesion, small molecule biochemistry aiming at changing intracellular concentrations of second messengers
such as Ca2+ and cAMP as well as expression of enzymes involved in posttranslational modification of proteins.
Conclusion: The current data provide novel candidate genes involved in neuronal differentiation, notably for the neuropoietic
cytokine IL-6. Our findings may also have impact on the clinical treatment of peripheral nerve injury. Local application of a
designer cytokine such as H-IL-6 with drastically enhanced bioactivity in combination with NTs may generate a potent reparative
microenvironment.
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Background
Interleukin-6 (IL-6) is the prototype member of the IL-6
cytokine family, also termed neuropoietic cytokines,
including IL-6, IL-11, IL-27, ciliary neurotrophic factor
(CNTF), leukemia inhibitory factor (LIF), oncostatin M,
cardiotrophin-1 (CT-1), cardiotrophin-like cytokine
(CLC; also known as novel neurotrophin 1, NNT1), neu-
ropoietin and B cell stimulatory factor 3 (BSF3) [1,2]. A
common feature of all family members is the signaling
through a specific receptor that is associated to the intrac-
ellularly located transduction component gp130. Subse-
quently, the Janus-activated kinase-signal transducer,
activator of transcription (JAK-STAT) and mitogen-acti-
vated protein kinase (MAPK) signal transduction path-
ways are activated. Neuropoietic cytokines display
multiple functions in the peripheral (PNS) and central
nervous systems (CNS), including the developing and
adult brain, synaptic plasticity as well as the brain's
response to injury and disease. In particular these mole-
cules control cell fate and differentiation of neural stem
and progenitor cells during development; due to their
neurotrophic and regenerative actions they crucially affect
injury-induced neurogenesis, neuronal survival and
regeneration; moreover, these molecules can also influ-
ence neuronal activity and are implicated in long-term
potentiation (LTP; reviewed in [2]).
Cellular functions of IL-6 are mediated by two specific
receptors, the membrane-bound 80 KDa IL-6 receptor (IL-
6R) or the soluble form of IL-6R (s-IL-6R) which can be
generated either by shedding of IL-6R or by alternative
splicing of the IL-6R mRNA [3,4]. Using s-IL-6R, IL-6
responsiveness may be conferred to cells expressing the
transduction component gp130, but are devoid of mem-
brane-bound IL-6R in the process of transsignaling [5-7].
The transsignaling mechanism led to the development of
a fusion protein in which IL-6 is covalently linked to s-IL-
6R thereby creating a unimolecular protein with
enhanced biological activities. The fusion protein, termed
Hyper-IL-6 (H-IL-6), turned out to be fully active at 100–
1000-fold lower concentrations as compared to the com-
bination of the two separate molecules [8,9].
The neurotrophin (NT) family of growth factors including
nerve growth factor (NGF), brain-derived neurotrophic
factor (BDNF), neurotrophin-3 (NT-3) and NT-4/5 is
important for development, maintenance and survival of
many different cell types in the PNS and the CNS [10].
NTs are also involved in regulating adult neurogenesis
[11,12], learning and memory [13,14]. NTs are synthe-
sized as proNT precursors that may be processed to
mature NTs intra- and extracellulary by specific proteases
[15]. NTs exert their effects via two different types of cellu-
lar receptors: pan-neurotrophin receptor p75 (p75NTR)
which binds all NTs with a similar affinity, and the family
of high affinity tyrosine kinase receptors (Trk). The inter-
actions of proNTs and NTs with the NT-receptors com-
prise a complex signaling system thus generating a broad
variety of biological effects [16,17].
In the first report of IL-6 actions on neural cells rat pheo-
chromocytoma cells (PC12), a well characterised cellular
model for neuronal differentiation, were incubated for up
to 6 days with B-cell stimulatory factor BSF-2/IL-6 thereby
inducing significant neurite outgrowth [18]. PC12 cells
that were differentiated either using irradiation [19] or the
well-known hypoxia mimetic agent CoCl2 [20] require IL-
6 expression. We have demonstrated that primary sympa-
thetic neurons [21] and PC12 cells [22] can strongly
respond to IL-6 by transsignaling, and that the potential of
IL-6 to induce neuronal differentiation in PC12 cells is in
close correlation to the availability of s-IL-6R [22,23].
PC12 cell differentiation is accompanied by enhanced
expression of GAP-43 mRNA at 24 hours after stimulation
with IL-6/s-IL-6R [22]. Moreover, we found that the
fusion protein H-IL-6 is a highly active molecule in induc-
ing survival of cultured sympathetic neurons, comparable
to the effects of NGF [21,22]. Recently, IL6RIL6, a fusion
protein in which IL-6 is directly linked to the extracellular
domain of the IL-6 specific receptor, has been used for
expression profiling studies in primary cultures of dorsal
root ganglia. In these cells, IL6RIL6 strongly increases
axonal network and expression of neural genes [24].
A significant problem in the clinical treatment of periph-
eral nerve injury is that the currently used therapeutic
approaches do not allow complete neuronal recovery
[25]. Mixtures comprising neuropoietic cytokines, glial
cell-line derived neurotrophic factor ligands (GFLs) and
NTs are being tested for the suitability to generate a micro-
environment with a high reparative potential upon local
administration at the site of the lesion [26].
In the present study we monitored changes in neuronal
gene expression induced by incubation of PC12 cells for
24 hours with H-IL-6 as well as NGF, and compared the
genetic programs utilized by these stimuli for neuronal
differentiation.
Results
Overall changes in gene expression patterns in IL-6- and 
NGF-stimulated PC12 cells
Affymetrix Gene Chip U34A arrays were used to analyse
global changes in gene transcripts using a cutoff in the
change of gene expression of > 2-fold. In PC12 cells stim-
ulated for 24 h with 10 ng/ml H-IL-6, we found 130 dif-
ferently expressed genes as compared to unstimulated
controls. Of them, 94 genes were upregulated with gene
expression values from 2-fold to 1085-fold, whereas 36
genes were found to be downregulated in the range fromBMC Genomics 2009, 10:90 http://www.biomedcentral.com/1471-2164/10/90
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-2-fold to -61-fold. The genes are further classified into
major functional categories including cytokines (2 up-reg-
ulated/0 down-regulated), enzymes (20/8), G-protein
coupled receptors (2/3), growth factors (7/1), ion chan-
nels (2/0), kinases (4/4), nuclear receptors (2/1), pepti-
dases (3/1), phosphatases (0/2), transcription regulators
(8/4), transmembrane receptors (5/0), transporters (8/3)
and molecules with other functions (31/9; Table 1).
In PC12 cells stimulated for 24 hours with 50 ng/ml NGF,
we identified 102 differently expressed genes as compared
to unstimulated controls. Of them, 71 genes were upregu-
lated with gene expression values from 2-fold to 303-fold,
whereas 31 genes were found to be downregulated by -2-
fold to -20-fold. Major functional categories include
enzymes (18 up-regulated/9 down-regulated), G-Protein
coupled receptors (2/2), growth factors (3/1), ion chan-
nels (7/2), kinases (6/2), peptidases (4/1), phosphatases
(2/1), transcription regulators (0/2), transmembrane
receptors (1/0), transporters (9/2) and molecules with
other functions (21/9; Table 2).
Only a small overlapping gene subset is shared by IL-6
and NGF comprising a total of 16 genes and including the
major functional categories enzymes (3 genes), G-Protein
coupled receptors (1), growth factors (1), ion channels
(2), kinases (1), peptidases (2), transporters (1) and mol-
ecules with other functions (5; Table 3). All genes are reg-
ulated in a parallel fashion except for caspase 1 with an
opposite expression pattern of IL-6 (40-fold) as compared
to NGF (-5-fold; Table 3). Tables 1, 2, 3 summarize gene
description names, Genbank accession numbers and
changes in expression levels derived from the Chip analy-
ses, gene symbols and abbreviations derived from the IPA
Tool.
Exemplary validation of microarray data using LightCycler 
quantitative RT-PCR analyses (qRT-PCR) on GAP-43 and 
REG3B mRNA expression
For an exemplary validation of the microarray data, qRT-
PCR using LightCycler was performed on GAP-43 and
REG3B mRNA expression. In the microarray analyses,
GAP-43 mRNA was found to be upregulated 3-fold by IL-
6 (Table 1), whereas qRT-PCR revealed an induction of
about 20-fold (Figure 1, left). In NGF-treated PC12 cells,
GAP-43 mRNA was found to be upregulated by < 2-fold
and therefore did not meet the exclusion criteria applied
in the current work. However, qRT-PCR analyses revealed
a 10-fold induction of GAP-43 mRNA levels induced by
NGF in PC12 cells (Figure 2). Thus, PC12 cells treated
with IL-6 or NGF undergo substantial neuronal differenti-
ation. REG3B mRNA expression in the microarray analysis
was found to be induced to 672-fold by IL-6 (Table 1),
whereas qRT-PCR revealed an induction of REG3B mRNA
by about 955-fold (Figure 1, right). In NGF-treated PC12
cells, neither microarray nor qRT-PCR analyses revealed
changes in RGE3B expression.
Ingenuity biological functional analyses of the gene sets 
regulated by IL-6 and NGF in PC12 cells
The criteria applied for the search of major biological
function categories were maximum number of genes and
the p-value of significance. As shown in Table 4, top bio-
logical functions found to be regulated by IL-6 include
cancer (61 genes), cellular growth and proliferation (54
genes), cell death (47 genes), cell-to-cell signalling and
interaction (46 genes), tissue development (45 genes) and
others. A further gene set is involved in nervous system
development and function (24 genes). The p-values in the
range of 2.26 × 10-7 to 3.77 × 10-3 indicate statistical sig-
nificance.
Similarly, in NGF-treated PC12 cells top biological func-
tions deal with the overall topics on cellular growth and
proliferation (37 genes), cell-to-cell signalling and inter-
action (31 genes), molecular transport (30 genes), cancer
(30 genes), cellular movement (29 genes) and others.
One gene set is involved in nervous system development
and function (29 genes). The p-values in the range from
8.89 × 10-6 to 7.43 × 10-3 indicate statistical significance
(Table 4).
More detailed analyses for functional sub-categories are
summarized in Table 5. Both stimuli utilize different rep-
ertoires of genes to exert the same biological functions
that are all crucial for neuronal differentiation and nerv-
ous system development. Among others, important func-
tional sub-categories include cellular growth (IL-6, 33
genes; NGF, 24 genes), differentiation (IL-6, 45 genes;
NGF, 16 genes), cell movement (IL-6, 39 genes; NGF, 27
genes), chemotaxis (IL-6, 13 genes; NGF, 13 genes), adhe-
sion of cells (IL-6, 26 genes; NGF, 18 genes), cellular sig-
nalling and small molecule biochemistry aiming at
changing intracellular concentrations of second messen-
gers such as Ca2+ (IL-6, 16 genes; NGF, 16 genes) as well
as cAMP (IL-6, 12 genes; NGF, 9 genes) as well as expres-
sion of posttranslational processing enzymes (IL-6, 23
genes; NGF, 15 genes). Table 5 (bottom) summarizes
genes involved in specialized sub-categories of nervous
system and development as far as they are represented in
the IPKB.
Discussion
In a previous study, we have used PC12 cells to examine
the effects of IL-6/s-IL6R on neuronal differentiation in
comparison to NGF [22]. Already after 24 hours of expo-
sure to IL-6/s-IL-6R or NGF PC12 cells are highly active in
cellular growth and proliferation displaying pronounced
formation of extending neurites. Combined incubation
with IL-6/s-IL-6 plus NGF drastically enhanced cellBMC Genomics 2009, 10:90 http://www.biomedcentral.com/1471-2164/10/90
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Table 1: List of gene set regulated by IL-6 in PC12 cells
Gene Accession no. Fold change Subcellular location
Cytokines
chemokine ligand 13 CXCL13 AF044196 43 Extracellular Space
chemokine ligand 10 CXCL10 U17035 7 Extracellular Space
Enzymes
cytochrome P450, 4f16 CYP4F16 U39207 424 Cytoplasm
ceruloplasmin CP AF202115 191 Extracellular Space
peptidyl arginine deiminase, type III PADI3 D88034 142 Cytoplasm
acyl-CoA synthetase, member 1 ACSL1 D90109 102 Cytoplasm
transglutaminase 1 TGM1 M57263 93 Plasma Membrane
nitric oxide synthase 2A NOS2A U03699 58 Cytoplasm
ornithine carbamoyltransferase OTC M11266 43 Cytoplasm
Similar to Lysophospholipase LOC374569 AB009372 37 Unknown
trehalase TREH AF038043 35 Plasma Membrane
kynureninase KYNU U68168 25 Cytoplasm
nitric oxide synthase 3 NOS3 AJ011115 21 Cytoplasm
glycine amidinotransferase GATM U07971 14 Cytoplasm
guanine nucleotide binding protein, alpha z GNAZ U77485 14 Plasma Membrane
ST6 galactosamide alpha-2,6-sialyltranferase 1 ST6GAL1 M83143 14 Cytoplasm
aldo-keto reductase, 1C1 AKR1C1 BAA92883 12 Cytoplasm
myxovirus resistance 1 MX1 P20591 9 Nucleus
aldolase C ALDOC X06984 3 Cytoplasm
2',5'-oligoadenylate synthetase 1 OAS1 Z18877 3 Cytoplasm
protein disulfide isomerise, A2 PDIA2 AAC50401 3 Cytoplasm
RNA (guanine-7-) methyltransferase RNMT BAA82447 3 Nucleus
polymerase, alpha 2 POLA2 AJ245648 -2 Nucleus
steroid-5-alpha-reductase, alpha 1 SRD5A1 J05035 -2 Cytoplasm
aminolevulinate, delta-, synthase 2 ALAS2 D86297 -3 Cytoplasm
glutathione S-transferase A3 GSTA3 X78847 -3 Cytoplasm
UDP glycosyltransferase 8 UGT8 BC075069 -3 Cytoplasm
cell division cycle 42 CDC42 U37720 -4 Cytoplasm
cysteine dioxygenase, type I CDO1 M35266 -4 Cytoplasm
ST8 alpha-2,8-sialyltransferase 3 ST8SIA3 X80502 -5 Cytoplasm
G-protein coupled receptors
adrenergic receptor, alpha-2B ADRA2B M32061 26 Plasma Membrane
arginine vasopressin receptor 2 AVPR2 AAB87678 5 Plasma Membrane
vasoactive intestinal peptide receptor 1 VIPR1 M86835 -2 Plasma Membrane
cholinergic receptor, muscarinic 3 CHRM3 AB017656 -3 Plasma Membrane
cholinergic receptor, muscarinic 4 CHRM4 M16409 -10 Plasma Membrane
Growth factors
regenerating islet-derived 3 alpha REG3A L10229 1084 Extracellular Space
regenerating islet-derived 3 beta REG3B S43715 672 Extracellular Space
growth differentiation factor 15 GDF15 AJ011970 80 Extracellular Space
platelet-derived growth factor alpha PDGFA M29464 69 Extracellular Space
nudix-type motif 6 NUDT6 AF188995 22 Extracellular Space
jagged 2 JAG2 U70050 5 Extracellular Space
hepatocyte growth factor HGF X84046 4 Extracellular Space
macrophage stimulating 1 MST1 X95096 -4 Extracellular Space
Ion channels
glutamate receptor, ionotropic, delta 2 GRID2 U08256 91 Plasma Membrane
purinergic receptor P2X P2RX2 Y10475 11 Plasma Membrane
Kinases
fyn-related kinase FRK U02888 122 Nucleus
Janus kinase 2 JAK2 U13396 120 Cytoplasm
phosphatidylinositol 4-kinase beta PI4KB D84667 2 CytoplasmBMC Genomics 2009, 10:90 http://www.biomedcentral.com/1471-2164/10/90
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pim-3 oncogene PIM3 AF086624 2 Unknown
fer tyrosine kinase FER X13412 -2 Cytoplasm
mitogen-activated protein kinase kinase 5 MAP2K5 U37462 -2 Cytoplasm
fibroblast growth factor receptor 1 FGFR1 S54008 -3 Plasma Membrane
activin receptor, type IIA ACVR2A S48190 -4 Plasma Membrane
Nuclear receptors
retinoic acid receptor alpha RARA U15211 20 Nucleus
nuclear receptor, *C2 NR3C2 M36074 8 Nucleus
vitamin D receptor VDR J03630 -4 Nucleus
Peptidases
complement component 1s C1S D88250 230 Extracellular Space
caspase 1 CASP1 U14647 40 Cytoplasm
proteasome subunit, alpha 1 PSMA1 M29859 5 Cytoplasm
kallikrein-related peptidase 8 KLK8 AJ005641 -5 Extracellular Space
Phosphatases
pyruvate dehydrogenase phosphatase 2 PDP2 AF062741 -4 Cytoplasm
protein tyrosine phosphatase receptor D PTPRD U57502 -9 Plasma Membrane
Transcription regulators
signal transducer and activator of transcription 1 STAT1 AF205604 579 Nucleus
Kruppel-like factor 6 KLF6 AF072403 249 Nucleus
HIV-1 Tat interacting protein HTATIP AAB18236 159 Nucleus
HIV enhancer binding protein 2 HIVEP2 D37951 65 Nucleus
upstream transcription factor 1 USF1 U41741 22 Nucleus
early growth response 1 EGR1 M18416 3 Nucleus
interferon regulatory factor 1 IRF1 M34253 3 Nucleus
signal transducer and activator of transcription 2 STAT2 AF206162 3 Nucleus
breast cancer 1 BRCA1 U36475 -2 Nucleus
D site of albumin promoter binding protein DBP J03179 -2 Nucleus
nuclear factor I/B NFIB Y07685 -2 Nucleus
transcription elongation factor A 2 TCEA2 D12927 -5 Nucleus
Transmembrane receptors
oxidized low density lipoprotein receptor 1 OLR1 AB018097 587 Plasma Membrane
histocompatibility 2, Q region locus 10 H2-Q10 M31018 160 Plasma Membrane
insulin-like growth factor 2 receptor IGF2R NM_000876 39 Plasma Membrane
Fc fragment of IgG receptor IIa (CD32) FCGR2A M64368 16 Plasma Membrane
growth hormone receptor GHR Z83757 12 Plasma Membrane
Transporters
cadherin 17 CDH17 X78997 273 Plasma Membrane
solute carrier family 6, member 3 SLC6A3 M80570 90 Plasma Membrane
nucleoporin 153kDa NUP153 L06821 83 Nucleus
solute carrier family 9, member 2 SLC9A2 L11004 32 Plasma Membrane
cadherin 17 CDH17 L46874 13 Plasma Membrane
lipocalin 2 LCN2 X13295 9 Extracellular Space
syntaxin 4 STX4 L20821 3 Plasma Membrane
secretory carrier membrane protein 2 SCAMP2 AF295405 2 Cytoplasm
solute carrier family 12, member 5 SLC12A5 U55816 -3 Plasma Membrane
solute carrier family 30, member 2 SLC30A2 U50927 -5 Plasma Membrane
syntaxin 5 STX5 U87971 -8 Cytoplasm
Others
regenerating islet-derived 1 alpha REG1A J05722 796 Extracellular Space
TIMP metallopeptidase inhibitor 1 TIMP1 L31883 210 Extracellular Space
calcitonin-related polypeptide beta CALCB M11596 195 Extracellular Space
fibrinogen gamma chain FGG J00734 164 Extracellular Space
trans-golgi network protein 2 TGOLN2 X53565 113 Cytoplasm
LIM and senescent cell antigen-like domains 1 LIMS1 AAA20086 94 Plasma Membrane
alpha-2-HS-glycoprotein AHSG M29758 80 Extracellular Space
Table 1: List of gene set regulated by IL-6 in PC12 cells (Continued)BMC Genomics 2009, 10:90 http://www.biomedcentral.com/1471-2164/10/90
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ribosomal protein L3-like RPL3L AAC50777 60 Unknown
collagen, type IV, alpha 5 COL4A5 AB041350 59 Extracellular Space
parvalbumin LOC4951 J02705 58 Unknown
YTH domain containing 1 YTHDC1 AF144731 39 Cytoplasm
growth hormone releasing hormone GHRH Z34092 31 Extracellular Space
annexin A1 ANXA1 M19967 29 Plasma Membrane
collagen, type XII, alpha 1 COL12A1 U57362 26 Extracellular Space
regenerating islet-derived 3 gamma REG3G L20869 24 Extracellular Space
adenylate cyclase activating polypeptide 1 ADCYAP1 S83513 20 Extracellular Space
heat shock protein 90 kDa, alpha B 1 HSP90AB1 S45392 20 Cytoplasm
luteinizing hormone beta LHB U25653 17 Extracellular Space
galectin 5 LGALS5 L36862 8 Extracellular Space
myocilin MYOC AF093567 8 Cytoplasm
prolactin family 8a81 PRL8A8 AB000107 8 Extracellular Space
troponin C type 2 TNNC2 J05598 8 Unknown
ribosomal protein L18a RPL18A X14181 7 Cytoplasm
fibrinogen beta chain FGB U05675 6 Extracellular Space
tropomyosin 3 TPM3 X72859 4 Cytoplasm
tubulin, beta TUBB AB011679 4 Cytoplasm
extracellular proteinase inhibitor EXPI X13309 3 Extracellular Space
growth associated protein 43 GAP43 M16736 3 Plasma Membrane
galectin 9 LGALS9 U72741 3 Extracellular Space
tubulin, alpha 4a TUBA4A M13444 3 Cytoplasm
BCL2-like 11 BCL2L11 AF136927 2 Cytoplasm
integrin alpha 7 ITGA7 X65036 -2 Plasma Membrane
syndecan 2 SDC2 M81687 -2 Plasma Membrane
zinc finger protein 260 ZNF260 U56862 -2 Nucleus
filamin C FLNC AF119148 -3 Cytoplasm
metallothionein 3 MT3 S65838 -3 Cytoplasm
arginine vasopressin AVP M25646 -4 Extracellular Space
fasciculation and elongation protein zeta 1 FEZ1 U63740 -4 Cytoplasm
crystallin, alpha B CRYAB U04320 -6 Nucleus
neurofascin NFASC U81036 -7 Plasma Membrane
Gene description names, gene symbols are from IPA Tool; accession numbers are from GenBank
Table 1: List of gene set regulated by IL-6 in PC12 cells (Continued)
Table 2: List of gene set regulated by NGF in PC12 cells
Gene Accession no. Fold change Subcellular location
Enzymes
rat senescence marker protein 2A gene SMP2A X63410 303 Cytoplasm
myosin, heavy chain 3 MYH3 K03468 133 Cytoplasm
lecithin-cholesterol acyltransferase LCAT X54096 101 Extracellular Space
UDP glucuronosyltransferase 2, polypeptide A1 UGT2A1 X57565 63 Cytoplasm
contactin 4 CNTN4 U35371 44 Plasma Membrane
phosphodiesterase 4B, PDE4B J04563 37 Cytoplasm
gulonolactone (L-) oxidase GULO J03536 34 Cytoplasm
superoxide dismutase 3 SOD3 Z24721 28 Extracellular Space
fibronectin 1 FN1 X15906 28 Plasma Membrane
acetylcholinesterase ACHE S50879 28 Plasma Membrane
tryptophan hydroxylase 1 TPH1 X53501 24 Cytoplasm
aldo-keto reductase family 1, member C1 AKR1C1 BAA92883 10 Cytoplasm
guanine nucleotide binding protein, alpha z GNAZ U77485 9 Plasma Membrane
aminoadipate aminotransferase AADAT Z50144 5C y t o p l a s m
phospholipase D2 PLD2 D88672 4C y t o p l a s m
N-deacetylase/N-sulfotransferase 1 NDST1 M92042 3C y t o p l a s m
phosphate cytidylyltransferase 2 PCYT2 AF080568 2C y t o p l a s m
peptidylprolyl isomerase A PPIA M19533 -2 Cytoplasm
Rab geranylgeranyltransferase alpha RABGGTA L10415 -2 Unknown
glutathione S-transferase A3 GSTA3 X78847 -3 Cytoplasm
cytochrome P450, 4F4 CYP4F4 U39206 -3 CytoplasmBMC Genomics 2009, 10:90 http://www.biomedcentral.com/1471-2164/10/90
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3-hydroxyanthranilate 3,4-dioxygenase HAAO D28339 -3 Cytoplasm
stearoyl-Coenzyme A desaturase 2 SCD2 AB032243 -4 Cytoplasm
aldo-keto reductase family 1, member C3 AKR1C3 L32601 -6 Cytoplasm
myxovirus resistance 2 MX2 X52711 -10 Nucleus
serine dehydratase SDS M38617 -11 Cytoplasm
G-protein coupled receptors
calcitonin/calcitonin-related polypeptide alpha CALCA V01228 136 Plasma Membrane
angiotensin II receptor 1 AGTR1 NM_009585 50 Plasma Membrane
cholinergic receptor, muscarinic 3 CHRM3 AB017656 -2 Plasma Membrane
parathyroid hormone receptor 1 PTHR1 M77184 -3 Plasma Membrane
Growth factors
growth differentiation factor 15 GDF15 AJ011970 131 Extracellular Space
transforming growth factor beta 1 TGFB1 X52498 101 Extracellular Space
brain-derived neurotrophic factor BDNF X67108 89 Extracellular Space
neuregulin 1 NRG1 U02324 -3 Extracellular Space
Ion channels
calcium channel, voltage-dependent, beta 2 CACNB2 M80545 90 Plasma Membrane
glutamate receptor, ionotropic, delta 2 GRID2 U08256 78 Plasma Membrane
sodium channel, voltage-gated, type II, beta SCN2B U37147 73 Plasma Membrane
potassium inwardly-rectifying channel J4 KCNJ4 X87635 51 Plasma Membrane
solute carrier family 9 member 3 SLC9A3 M85300 40 Plasma Membrane
purinergic receptor P2X, ligand-gated ion channel 2 P2RX2 Y10475 13 Plasma Membrane
sodium channel, voltage-gated, type I, alpha SCN1A M22253 12 Plasma Membrane
purinergic receptor P2X-like 1 P2RXL1 X92070 -2 Plasma Membrane
gamma-aminobutyric acid A receptor gamma 2 GABRG2 X56313 -19 Plasma Membrane
Kinases
G protein-coupled receptor kinase 5 GRK5 NM_005308 131 Plasma Membrane
protein kinase, cGMP-dependent, type II PRKG2 Z36276 68 Cytoplasm
mitogen-activated protein kinase kinase kinase kinase 1 MAP4K1 Y09010 25 Cytoplasm
calcium/calmodulin-dependent serine protein kinase CASK U47110 3 Plasma Membrane
discs, large homolog 1 DLG1 U14950 3 Plasma Membrane
phosphatidylinositol 4-kinase beta PI4KB D84667 3C y t o p l a s m
discoidin domain receptor family member 1 DDR1 L26525 -8 Plasma Membrane
non-metastatic cells 6 NME6 AF051943 -14 Extracellular Space
Peptidases
carboxypeptidase A3 CPA3 U67914 5 Extracellular Space
ADAM metallopeptidase domain 17 ADAM17 AJ012603 4 Plasma Membrane
Proteasome subunit alpha 1 PSMA1 M29859 3C y t o p l a s m
protein disulfide isomerase family A member 3 PDIA3 D63378 2C y t o p l a s m
caspase 1 CASP1 U14647 -5 Cytoplasm
Phosphatases
dual specificity phosphatase 6 DUSP6 U42627 53 Cytoplasm
protein phosphatase 1 subunit 1A PPP1R1A AJ276593 18 Cytoplasm
protein tyrosine phosphataser type 11 PTPN11 U09307 -2 Cytoplasm
Transcription regulators
jun dimerization protein 2 JDP2 U53449 -2 Nucleus
cAMP responsive element modulator CREM Z15158 -4 Nucleus
Transmembrane receptors
cholinergic receptor, nicotinic, beta 1 CHRNB1 X74833 39 Plasma Membrane
Transporters
solute carrier family 1 member 1 SLC1A1 U21104 238 Plasma Membrane
solute carrier family 22, member 3 SLC22A3 AF055286 95 Plasma Membrane
gap junction protein, beta 2 GJB2 X51615 55 Plasma Membrane
solute carrier family 1, member 3 SLC1A3 S59158 6 Plasma Membrane
solute carrier family 22, member 6 SLC22A6 AF008221 6 Plasma Membrane
vacuolar protein sorting 33 homolog B VPS33B U35245 4C y t o p l a s m
solute carrier family 30, member 1 SLC30A1 U17133 3 Plasma Membrane
syntaxin 4 STX4 L20821 2 Plasma Membrane
murinoglobulin 1 MUG1 J03552 -2 Extracellular Space
ATPase, Cu++ transporting, beta polypeptide ATP7B AF120492 -6 Cytoplasm
Table 2: List of gene set regulated by NGF in PC12 cells (Continued)BMC Genomics 2009, 10:90 http://www.biomedcentral.com/1471-2164/10/90
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number and neurite outgrowth arguing for an additive
effect of both stimuli on neuronal differentiation. In the
current study we have chosen this time point to perform
microarray analyses in order to monitor changes in gene
expression and to compare the genetic programs utilized
for neuronal differentiation by IL-6 versus NGF.
An important aspect in gene expression profiling using
microarrays is the accuracy of the measurements in the rel-
ative changes in mRNA expression. Thus, alternative tech-
nologies such as qRT-PCR are used for the validation of
microarray data [27]. Several systematic studies compar-
ing the changes in gene expression obtained from oligo-
nucleotide- or cDNA arrays to data from qRT-PCR
revealed that a good correlation exists for genes exhibiting
fold-change differences in expression of > 2-fold [28,29].
Therefore, in our datasets all genes displaying changes in
expression levels of < 2-fold were excluded. Moreover, our
exemplary validation data on GAP-43- and REG3B-
expression are in line with other previous reports confirm-
ing that it is rather the magnitude of fold change varying
between qRT-PCR and Affymetrix-analysis, but not the
direction.
Detailed Ingenuity biological function analyses reveal
that IL-6 and NGF activate gene sets that regulate the same
process in neuronal differentiation and nervous system
development, however, utilizing completely distin-
guished sets of individual molecules. This may explain
our previous observation that combined application of IL-
6/s-IL-6R plus NGF generates an additive effect on PC12
cell differentiation. Important processes in neuronal dif-
ferentiation and nervous tissue development include cel-
lular growth and proliferation in order to enhance cell
number. Neurite outgrowth and network generation
requires migration of neurons or nerve growth cones.
Neuronal navigation is guided by the interaction of the
neuron with its local environment, in particular by chem-
otaxis as the key mechanism. This process involves three
major steps including directional sensing along a gradient
of chemotactic factors, cellular motility i.e. the cell's
movement by changes in cytoskleletal organisation and
Table 3: Set of genes commonly regulated by IL-6 and NGF in PC12 cells
Gene Fold change
IL-6 NGF
Enzymes
guanine nucleotide binding protein, alpha z GNAZ 14 9
glutathione S-transferase A3 GSTA3 - 3 - 3
aldo-keto reductase family 1, member C1 AKR1C1 12 10
G-protein coupled receptors
cholinergic receptor, muscarinic 3 CHRM3 - 3 - 2
Growth factors
growth differentiation factor 15 GDF15 80 131
Ion channels
glutamate receptor, ionotropic, delta 2 GRID2 91 78
purinergic receptor P2X, ligand-gated ion channel P2RX2 11 13
Kinases
phosphatidylinositol 4-kinase beta PI4KB 2 3
Peptidases
caspase 1 CASP1 40 - 5
proteasome subunit alpha 1 PSMA1 5 3
Transporters
syntaxin 4 STX4 3 2
Others
trans-golgi network protein 2 TGOLN2 113 106
LIM and senescent cell antigen-like domains 1 LIMS1 94 75
fibrinogen gamma chain FGG 94 3
collagen, type XII, alpha 1 COL12A1 26 28
extracellular proteinase inhibitor EXPI 3 3
Gene description names, gene symbols are from IPA ToolBMC Genomics 2009, 10:90 http://www.biomedcentral.com/1471-2164/10/90
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cellular adhesion and cellular polarisation [30-32]. Cer-
tainly, a key step in the regulation of these processes is the
increased gene expression of growth factors and function-
ally related external molecules, indicating convergence of
several different signaling pathways (Table 5). In IL-6
stimulated PC12 cells these tasks may be taken by growth
differentiation factor 15 (GDF15), platelet-derived
growth factor alpha (PDGFA), hepatocyte growth factor
(HGF), regenerating islet-derived 3 alpha (REG3A), regen-
erating islet-derived 3 beta/pancreatitis-associated protein
I (REG3B/PAPI), growth hormone releasing hormone
(GHRH) and adenylate cyclase activating polypeptide
(PACAP). NGF recruits GDF15 (131-fold), transforming
growth factor beta 1 (TGFB1; 101-fold) and brain-derived
neurotrophic factor (BDNF; 89-fold). TGFB1 is the proto-
type member of the TGFB-superfamily comprising multi-
functional growth factors with numerous cell and tissue
functions such as cell cycle control, regulation of early
development, differentiation, extracellular matrix (ECM)
formation and chemotaxis. In the nervous system, TGFB1
has been shown to regulate neuroprotection against gluta-
mate cytotoxicity, ECM production, and cell migration in
the cerebral cortex, control of neuronal death as well as
survival of neurons (reviewed in [33]). GDF15 is a mem-
ber of the TGFB- superfamily and has been shown to be a
potent trophic factor in the brain (reviewed in [34]).
Hepatocyte growth factor (HGF) is a chemoattractant and
a survival factor for embryonic motor neurons. In addi-
tion, sensory and sympathetic neurons and their precur-
sors respond to HGF with increased differentiation,
survival and axonal outgrowth [35]. Moreover, HGF may
synergize with other neurotrophic factors to potentiate
the response of developing neurons to specific signals
[36]. Platelet derived growth factor (PDGF) has been sug-
gested to support neuronal differentiation [37], and has
previously been reported to act as a mitogen for immature
neurons [38] and neural progenitor cells [39]. REG3A and
REG3B/PAPI are members of the regenerating protein
(REG)/pancreatitis-associated protein (PAP) family repre-
senting a complex group of small secretory proteins which
display many different functions, among them growth
factor activity for neural cells [40]. So far, only limited
knowledge is available about the role and function of
PAP/REG-proteins in the nervous system. REG3B/PAPI
expression is induced in spinal motor neurons as well as
subsets of the dorsal root ganglion neurons [41]. Moreo-
ver,  in vitro REG3B/PAPI has a mitogenic effect on
Schwann cells [42]. In a hypoglossal nerve injury model
in rats, expression of REG3B/PAPI mRNA was found to be
enhanced in injured motor neurons after axotomy and a
marked induction of REG3G/PAPIII mRNA was observed
in the distal part of the injured nerve [43]. More recently,
REG3G/PAPIII has been identified as a macrophage che-
moattractant that is induced in and released from injured
nerves [44]. With REG1A/PSP and REG3G/PAPIII, two
further members of the REG/PAP family are induced by
IL-6 in PC12 cells. It is noteworthy that these genes are up-
regulated at the highest levels obtained in the entire data-
set for IL-6. In NGF-treated PC12 cells, no up-regulation
of the PAP/REG protein genes was observed. The results in
our study are in line with an earlier report demonstrating
up-regulation of PAP/REG gene family members in PC12
cells upon stimulation with IL-6/s-IL-6R [45].
So far various studies have investigated gene expression
profiles in NGF-treated PC12 cells applying different
experimental protocols in respect to time points and peri-
ods of NGF administration [46-51]. From most studies, it
is obvious that PC12 cells require at least 3 to 5 days of
NGF-treatment to obtain the fully differentiated neuronal
phenotype. The most significant morphological changes
occur within the first 2 days, reaching a plateau phase at
day 3 [51]. Redundant data sets as well as unique genes
have been identified and followed. Our study provides
novel candidate genes activated in the early phase of the
differentiation process and thus may enlarge the reper-
toire of known NGF-regulated genes.
The current study reveals novel aspects of IL-6 action,
notably that it applies several major routes to direct PC12
cell differentiation. Besides up-regulation of growth fac-
tors known to act in autocrine and paracrine fashion to
take over further tasks in the differentiation process, these
include induction of PACAP, a pleiotropic molecule with
a broad spectrum of biological functions. Among them
are actions as a neurotrophic factor similar to NGF as well
as induction of transcription factors known to be of key
importance in neuronal differentiation [52].
Changes in expression of GAP-43- and REG3B mRNA levels  in IL-6-stimulated PC12 cells determined by qRT-PCR versus  GeneChip Figure 1
Changes in expression of GAP-43- and REG3B 
mRNA levels in IL-6-stimulated PC12 cells deter-
mined by qRT-PCR versus GeneChip. Affymetrix Gene-
chip- and qRT-PCR analyses were performed as described in 
the Methods section.BMC Genomics 2009, 10:90 http://www.biomedcentral.com/1471-2164/10/90
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Upregulation of PACAP could have an important impact
on IL-6-induced PC12 cell differentiation. A recent report
provided data from microarray analyses of PACAP-regu-
lated gene transcripts in primary cultures of sympathetic
neurons at 6 hours and 92 hours of stimulation [53]. A
comparison with our data reveals that many gene families
that are activated by PACAP in primary sympathetic neu-
rons are also induced by IL-6 in PC12 cells (Table 6).
Thus, many of the effects of IL-6 on PC12 cells are likely
to be mediated by the intermediate autocrine and/or para-
crine action of PACAP. PACAP is a member of a family of
neuropetides known to activate class II G-protein coupled
receptors (GPCRs; reviewed in [54]). Other family mem-
bers include growth hormone releasing hormone
(GHRH) and calcitonin-related peptide beta (CALCB)
which are activated by IL-6 in PC12 cells by 31-and 195-
fold, respectively. All members of the class II GPCR super-
family regulate intracellular cAMP-levels by receptor cou-
pling to the Gs-adenylate cyclase-cAMP signaling pathway
[54]. A further mechanism of PACAP action in PC12 cells
could be a transactivation of TrkA receptors [55]. How-
ever, in light that the overlap in the datasets of IL-6 versus
NGF is rather small, TrkA activation may not be a primary
event at all or at the time point of our study.
A further key step in IL-6 actions on PC12 cell differentia-
tion is the induction of RARA and EGR-1/Zif268, two
transcription factors known to be of crucial importance in
neuronal differentiation. Among the genes regulated by
retinoic acid is GAP-43, a neuron specific protein fre-
quently used as a marker of neuronal differentiation as it
is expressed in most neurons during neuronal develop-
ment, nerve regeneration and LTP [56-60]. The data
herein are confirmative to our previous study in which we
have found induction of GAP-43 mRNA upon stimula-
tion of PC12 cells with IL-6/s-IL-6R [22]. EGR-1/Zif268 is
induced in nearly every model of long-lasting synaptic
plasticity in the CNS [61-64] and suppression of Zif268
prevents neurite outgrowth in PC12 cells [65]. Recently
candidate target genes of Zif268 in PC12 cells were iden-
tified suggesting that a key component of the long-lasting
effects of Zif268 on CNS plasticity is the regulation of pro-
teasome activity [66,67].
Signal transducer and activator of transcription 1/2
(STAT1/2), two members of the STAT family of transcrip-
tions factors involved in signaling by Interferons (IFN)
[68] are activated by stimulation of the PC12 cells with IL-
6. As we could not detect changes in IFN gene expression,
an autocrine action of PDGF is the most likely candidate
for upregulation of STAT1/2 as described for neural pro-
genitor cells [39]. STAT1/2 may upregulate interferon reg-
ulatory factor 1(IRF1)-expression, a further transcription
factor of IFN-signaling. Breast cancer 1 (BRCA1) encodes
a tumour suppressor gene whose germ line mutations in
women are associated with a genetic predisposition to
breast and ovarian cancer. STAT1 transcriptional activity is
decreased by a physical interaction with BRCA1 as a key
step in the regulation of IFN-induced cellular growth
arrest [69]. By the action of IL-6, BRCA1 gene expression
is down-regulated thus supporting STAT1 mediated PC12
cell growth. We failed to detect STAT3 expression, the key
transcription factor of IL-6 signaling. This is most likely
due to the fact that STAT3 gene transcription occurs very
early in IL-6-stimulation and is already terminated at the
time point of the analysis, or the expression levels are
below 2-fold and thus did not meet the exclusion criteria.
The morphological changes during nervous system devel-
opment are controlled by interactions of individual neu-
rons with the ECM. Signals from the ECM into a particular
neuron are mediated by integrins via associated adapter
molecules. In this way growth factor induced receptor
tyrosine kinase (RTK)- and integrin-mediated signalling
determine the fate of a particular cell, notably differentia-
tion, cell shape, adhesion, polarity, migration, as well as
proliferation versus apoptotic cell death (reviewed in
[70]). LIM and senescent cell antigen-like domains1/
PINCH (LIMS1/PINCH) is an intracellular adaptor mole-
cule providing the molecular link of an integrin-RTK net-
work. LIMS1 physically connects integrin-linked kinase
(ILK) to non-catalytic (region of) tyrosine kinase adaptor
protein 2 (Nck2), an adapter molecule of the growth fac-
tor receptor (RTK) [70]. LIMS1 is activated by IL-6 as well
as NGF and thus is one of few genes regulated in the com-
mon subset. In contrast to IL-6, NGF simultaneously up-
regulates major components of the ECM including colla-
gen, type XI, alpha1 (COL11A1), COL12A1, fibronectin1
(FN1) as well as fibrillin2 (FN2) (Table 2).
Changes in expression of GAP-43- mRNA levels in IL-6- ver- sus NGF-stimulated PC12 cells Figure 2
Changes in expression of GAP-43- mRNA levels in IL-
6- versus NGF-stimulated PC12 cells. qRT-PCR analy-
ses were performed as described in the Methods section.BMC Genomics 2009, 10:90 http://www.biomedcentral.com/1471-2164/10/90
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In contrast to NGF, only one publication provided expres-
sion profiling data analysing gene sets regulated by IL-6
upon neuronal differentiation. Primary cultures of rat
dorsal root ganglia (DRG) were treated with IL6RIL6 for 2
and 4 days, respectively. A detailed comparison reveals
that only a small number of commonly regulated genes
may be identified in the datasets that are regulated in par-
allel or opposite direction. These include Egr-1 (upregu-
lated in PC12 cells; downregulated in DRG cells), TGFA
(upregulated in PC12 cells and DRG cells), TGFB (upreg-
ulated in PC12 cells; downregulated in DRG cells),
PDGFA (upregulated in PC12 cells; downregulated in
DRG cells) and IRF-1 (upregulated in PC12 cells and in
DRG cells) [24].
The results obtained from our study may also have impact
into clinical treatments of injured peripheral nerves
which, in contrast to central nerves, have the ability to
recover from damage. Currently the therapy of choice is
the use of autologous grafts where the defect is bridged
with a section of autologous nerve tissue, mostly a sensory
nerve [71]. Alternatively, nerve conduits or decellularized
nerve grafts can be used; however, no therapy could yield
a satisfactory functional recovery [72]. Various combina-
tions of NTs, neuropoietic cytokines and GFLs have been
shown to generate a microenvironment suitable to
improve nerve repair [26]. The results of our study may
provide novel aspects for the treatment of peripheral
nerve injury as the local application of a designer cytokine
such as H-IL-6 with a strongly enhanced bioactivity on
neuronal development and neurite outgrowth in combi-
nation with NTs and/or GFLs may create a microenviron-
ment with a strong reparative potency.
Conclusion
IL-6 and NGF utilize different genetic programs to exert
the same biological functions in neuronal differentiation.
An important step is the recruitment of many growth fac-
tors that may act in autocrine and/or paracrine fashion
and may control the long-term effects on growth, neuro-
nal differentiation or survival.
Methods
Reagents, buffers and cells
DMEM medium, horse serum, fetal bovine serum and
other cell culture supplements were obtained from Gibco-
BRL. TRIZOL reagent and Superscript reverse transcriptase
were purchased Life Technologies. PC12 cells were
obtained from ATCC, Manassas (VA), USA. Hyper-IL-6
was generated as described [8]. The LightCycler PCR kit
was from Roche Diagnostics, Mannheim, Germany.
Cell culture
PC12 cells were cultured in DMEM medium containing
10% fetal bovine serum and 100 U/ml penicillin and
streptomycin at 37°C in humidified 5% CO2/95% air. For
stimulation confluent cells were washed once with PBS
and cultured in cell culture medium containing 10 ng/ml
H-IL-6 or 50 ng/ml recombinant human NGF for 24
hours. Control cells were incubated in cell culture
medium alone for 24 hours.
Table 4: Top high-level functions identified by Ingenuity global function analysis of regulated genes in IL-6-versus NGF- stimulated PC 
12 cells
Biological function classification Number of genes Significance (p-value)
IL-6-regulated genes
Cancer 61 2.98 × 10-6 to 5.16 × 10-3
Cellular Growth and Proliferation 54 1.14 × 10-6 to 5.16 × 10-3
Cell Death 47 4.54 × 10-6 to 5.16 × 10-3
Cell-to-Cell Signalling and Interaction 46 2.26 × 10-7 to 5.16 × 10-3
Tissue Development 45 2.26 × 10-7 to 5.15 × 10-3
Cellular Movement 39 9.19 × 10-6 to 5.16 × 10-3
Cellular Development 38 8.56 × 10-6 to 4.85 × 10-3
Small Molecule Biochemistry 37 1.32 × 10-5 to 4.47 × 10-3
...
Nervous system development and function 24 2.83 × 10-5 to 3.77 × 10-3
NGF-regulated genes
Cellular growth and proliferation 37 7.86 × 10-5 to 8.88 × 10-3
Cell-to-cell signalling and interaction 31 1.03 × 10-4 to 7.43 × 10-3
Molecular transport 30 8.89 × 10-6 to 8.70 × 10-3
Cancer 30 1.03 × 10-4 to 7.43 × 10-3
Cellular movement 29 2.41 × 10-5 to 8.70 × 10-3
Cell death 29 2.73 × 10-5 to 8.77 × 10-3
Neurological diseases 29 1.07 × 10-4 to 8.70 × 10-3
Nervous system development and function 29 1.60 × 10-4 to 8.70 × 10-3
p-values are from IPA ToolBMC Genomics 2009, 10:90 http://www.biomedcentral.com/1471-2164/10/90
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Table 5: Ingenuity biological function analyses of IL-6-versus NGF-regulated genes in PC12 cells (selected)
IL-6 regulated genes in PC12 cells NGF-regulated genes in PC12 cells
Category p-value Molecules p-value Molecules
Sub-Category or 
Function annotation
Cellular Growth and 
Proliferation
Growth of cells 2.27 × 10-4 ACVR2A, AHSG, ANXA1, BCL2L11, 
BRCA1, CASP1, CDC42, CHRM3, 
CXCL10, EGR1, FGFR1, GAP43, GDF15, 
GHR, GRID2, HGF, IGF2R, IRF1, ITGA7, 
JAK2, MAP2K5, MST1, MT3, MX1, NOS3, 
NOS2A, PIM3, RARA, SCAMP2, SDC2, 
STAT1, TIMP1, VDR
8.82 × 10-3 ACHE, AGTR1, BDNF, BNIP3, CASP1, CD44, 
CHRM3, CREM, DDR1, DUSP6, FBN2, FN1, 
GDF15, GJB2, GRID2, MYL9, NRG1, PDIA3, 
PTPN11, SLC30A1, TGFB1, TPM1, VPS33B, 
ZMAT3
Proliferation of cells 9.06 × 10-7 ACVR2A, ADCYAP1, ANXA1, AVP, 
BCL2L11, BRCA1, CALCB, CDC42, 
CHRM3, CHRM4, CRYAB, CXCL10, 
EGR1, FGFR1, FRK, GDF15, GHR, GHRH, 
HGF, IGF2R, IRF1, JAG2, JAK2, KLF6, 
KLK8, LCN2, MAP2K5, MT3, NFIB, NOS3, 
NOS2A, NR3C2, PDGFA, RARA, REG1A, 
REG3A, RNMT, SDC2, ST6GAL1, STAT1, 
TIMP1, TPM3, USF1, VDR, VIPR1
3.82 × 10-3 AGTR1, AKR1C3, BDNF, CALCA, CD44, 
CHRM3, DDR1, FN1, GDF15, GRK5, NPPC, 
NRG1, PPIA, PTPN11, TAC1, TGFB1
Cellular Movement
Cell movement 2.18 × 10-8 ADCYAP1, ANXA1, CASP1, CDC42, 
CHRM3, CHRM4, CXCL10, CXCL13, 
EGR1, FCGR2A, FER, FGB, FGFR1, GNAZ, 
GRID2, HGF, HLA-G, HSP90AB1, IGF2R, 
JAK2, LCN2, LGALS9, LIMS1, MAP2K5, 
MST1, NOS3, NOS2A, OLR1, PDGFA, 
RARA, REG3A, SDC2, ST6GAL1, STAT1, 
TIMP1, TPM3, TUBB, VDR, VIPR1
7.96x10-5 ADAM17, AGTR1, APCS, BDNF, CALCA, 
CASP1, CD44, CHRM3, DDR1, FN1, GJB2, 
GNAZ, GRID2, LCAT, LIMS1, NAP1L4, 
NPPC, NRG1, PDE4B, PPIA, PTPN11, 
SCN2B, SELP, SLC1A3, TAC1, TGFB1, TPM1
Chemotaxis 4.05 × 10-4 ANXA1, CDC42, CXCL10, CXCL13, 
FCGR2A, FER, FGFR1, GNAZ, HGF, 
IGF2R, LGALS9, NOS3, VIPR1
6.29x10-5 AGTR1, BDNF, CALCA, CD44, FN1, GNAZ, 
NAP1L4, PDE4B, PPIA, PTPN11, SCN2B, 
TAC1, TGFB1
Cell-To-Cell 
Signaling and 
Interaction
Adhesion of cells 1.47 × 10-7 ANXA1, CDC42, CDH17, CXCL10, 
EGR1, FCGR2A, FER, FEZ1, FGB, FGFR1, 
FGG, GRID2, HGF, IGF2R, ITGA7, JAG2, 
LGALS9, LIMS1, NOS3, OLR1, REG3A, 
SDC2, ST6GAL1, STAT1, STX4, TIMP1
1.34x10-4 ACHE, ADAM17, CASK, CD44, CNTN4, 
DDR1, DLG1, FGG, FN1, GRID2, LIMS1, 
NRG1, PTPN11, SELP, STX4, TAC1, TGFB1, 
TPH1
Cell Signaling
Quantity of calcium 3.25 × 10-3 ADCYAP1, AVP, CHRM3, CXCL10, 
CXCL13, FCGR2A, GHRH, HGF, NOS3, 
NOS2A, VDR
8.89x10-6 AGTR1, BDNF, CALCA, CHRM3, FN1, 
GRK5, NPPC, PLD2, PPIA, PTHR1, PTPN11, 
SELP, TAC1, TGFB1
Production of nitric 
oxide
1.33 × 10-3 IRF1, JAK2, MST1, NOS3, NOS2A, STAT1 - -
Flux of calcium 1.67 × 10-3 ADCYAP1, ANXA1, AVP, CHRM3, 
CXCL10, CXCL13, FCGR2A, P2RX2
2.20x10-3 CALCA, CHRM3, FN1, NPPC, P2RX2, PPIA, 
TGFB1
Cell surface receptor 
linked signal 
transduction
1.45 × 10-3 ACVR2A, ANXA1, CDC42, CXCL10, 
FCGR2A, FGFR1, ITGA7, JAK2, KLF6, 
LIMS1, PDGFA, PTPRD, STAT1
--
Small Molecule 
Biochemistry
Quantity of cyclic AMP 1.00 × 10-5 ADCYAP1, AVP, CHRM4, CXCL10, 
GAP43, GHRH, GNAZ, NOS3, VIPR1
6.03x10-3 BDNF, CALCA, GNAZ, NPPC, PTHR1
Production of cyclic 
AMP
2.17 × 10-4 ADCYAP1, AVP, GHRH, GNAZ, NOS3, 
NOS2A, VIPR1
Accumulation of cyclic 
AMP
1.21 × 10-3 ADCYAP1, AVP, AVPR2, CHRM3, GHRH, 
VIPR1
4.35 × 10-4 CALCA, CHRM3, GRK5, PTHR1, TAC1, 
TGFB1
Formation of cyclic AMP 1.28 × 10-4 ADCYAP1, AVP, AVPR2, GHRH, GANZ 7.26 × 10-4 CALCA, GNAZ, PTHR1, TAC1
Release of Ca2+ 9.82 × 10-5 ANXA1, AVP, CHRM3, FCGR2A, FGB, 
FGG
--
Quantity of cholesterol - - 2.85 × 10-3 ATP7B, BDNF, CALCA, GULO, LCATBMC Genomics 2009, 10:90 http://www.biomedcentral.com/1471-2164/10/90
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RNA Preparation
Total RNA from unstimulated (control), H-IL-6- and
NGF- stimulated PC12 cells was isolated using TRIZOL
reagent according to the manufacturer's instructions. RNA
was quantified spectrophotometrically by measuring the
absorbance at 260 nm and the integrity was checked by
formaldehyde agarose gel electrophoresis. The extracted
RNA was stored at -80°C.
GeneChip analysis
20 μg of total RNA was used for each experiment and the
target cRNA for Affymetrix Gene Chip analysis was pre-
pared according to the manufacturer's instructions.
Affymetrix GeneChip Rat Genome U34A arrays contain-
ing each 8'799 probes including full-length or annotated
rat genes and several thousands of rat EST clusters consist-
ing of redundant probes spanning an identical transcript
were hybridized with the target cRNAs at 45°C for 16 h,
washed and stained by using the Gene Chip Fluidics Sta-
tion. The arrays were scanned with the Gene Array scanner
(Affymetrix), and the fluorescence images obtained were
processed by the Expression Analysis algorithm in
Affymetrix Microarray Suite (ver. 4.0) and Microsoft Excel.
Data were imported into GeneSpring® analysis software
(ver. 4.1.3, Silicon Genetics, Redwood City, CA) for fur-
ther analysis. Genes that showed substantial up- or down-
regulation after stimulation by fold changes > 2 were
selected from three independent experiments. Genes
whose fold change was < 2 and expressed sequence tags
(ESTs) that were not fully identified were excluded from
the gene list. Thus, only genes with a change fold cutoff >
2 were considered to be significantly differentially regu-
lated. Values are given as round off numbers. For each
condition (unstimulated control- and H-IL-6-simulated
PC12 cells or unstimulated control and NGF-stimulated
PC12 cells) 3 independent microarray analyses (n = 3)
were performed using RNA samples derived from inde-
pendently prepared cell culture batches.
Quantitative Real Time PCR (qRT-PCR)
Total RNA (10 μg) from individual samples cultured sep-
arately from those used for microarray analyses was
Post-Translational 
Modification
Modification of protein 1.57 × 10-5 AVP, BRCA1, CASP1, CHRM3, FCGR2A, 
FER, FGFR1, GRID2, HSP90AB1, HTATIP, 
JAK2, LHB, MST1, NOS3, NOS2A, 
PDGFA, PDIA2, PDP2, PIM3, PTPRD, 
ST6GAL1, STAT1, TGM1
4.47 × 10-3 APCS, CASP1, CD44, CHRM3, DUSP6, FN1, 
GRID2, NDST1, NRG1, PDIA3, PPIA, 
PTPN11, RABGGTA, TAC1, UBB
Nervous system 
development and 
function
growth of neurites 8.02 × 10-3 ADCYAP1, CDC42, GAP43, HGF, TPM3 - -
survival of neurons 3.60 × 10-3 ADCYAP1, BCL2L11, GDF15, HGF, 
RARA, REG3A
--
development of synapse 6.57 × 10-3 GRID2, NFASC - -
fasciculation of axons 3.14 × 10-2 GAP43 - -
complexity of dendritic 
trees
1.25 × 10-2 HGF - -
long-term potentiation 
of dentate gyrus
1.25 × 10-2 EGR1 - -
neurological process of 
synapse
- - 1.60 × 10-4 BDNF, CHRM3, CHRNB1, NRG1, PPP1R1A
synaptic transmission - - 2.88 × 10-4 BDNF, CACNB2, CHRM3, CHRNB1, 
GABRG2, P2RX2, SCN2B, SLC1A1, SLC1A3
neurological process of 
axons, neurites
- - 4.79 × 10-4 BDNF, CNTN4, GRID2, NRG1, PDIA3, UBB
activation of nerves - - 7.73 × 10-4 CALCA, TAC1
binding of neurites - - 7.73 × 10-4 BDNF, CD44
size of cell body - - 7.73 × 10-4 ACHE, BDNF
survival of neurons - - 8.92 × 10-4 BDNF, GDF15, NRG1, PDIA3, SLC1A3, 
TGFB1
development of neurites - - 2.83 × 10-3 ACHE, BDNF, GRID2, NRG1, PDIA3, 
PTPN11
migration of nervous 
tissue cell lines
- - 3.38 × 10-3 NRG1, TGFB1
proliferation of nervous 
tissue cell lines
- - 6.67 × 10-3 NPPC, TGFB1
-, no subcategories found in IPA Tool; p-values and gene symbols are from IPA Tool
Table 5: Ingenuity biological function analyses of IL-6-versus NGF-regulated genes in PC12 cells (selected) (Continued)BMC Genomics 2009, 10:90 http://www.biomedcentral.com/1471-2164/10/90
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Table 6: Comparison of commonly regulated gene families in PACAP-stimulated sympathetic primary neurons versus IL-induced 
PC12 cells (data derived from [53])
PACAP-stimulated sympathetic neurons (data are from [53]) IL-6-stimulated PC12 cells
Gene family
Gene abbreviation 9 hours 96 hours Gene abbreviation 24 hours
Pituitary adenylate cyclase activating polypeptide
ADCYAP1 + + ADCYAP1 +
BCL2-like protein
BCL2L11 + n.c. BCL2L11 +
Chemokine Ligands
CXCL1 ++
CXCL10 +
CXCL13 +
Cytochrome P450 proteins
CYP1B1 ++
CYP4F16 +
Early growth response
EGR1 +n . c . E G R 1 +
Glutathione S-transferase
GSTA3 +n . c . G S T A 3 -
Heat shock proteins
HSP27B1 +n . c . H S P 9 0 B 1 +
Janus kinase
JAK2 +J A K 2 +
Kruppel-like factors
KLF4 +n . c . K L F 6 +
KLF9 +n . c .
Nuclear factors
NFIA +n . c . N F I B +
Nuclear receptors
NR4A3 +n . c .
NR4A2 +n . c .
NR4A1 +n . c .
NR3C2 +
Sialytransferases
ST8SIA1 ++ S T 8 S I A 3 -
ST6GAL1 ++ S T 6 G A L 1 +
Solute carrier proteins
SLC1A3 +n . c .
SLC2A1 +
SLC2A3 ++
SLC6A3 +
SLC7A1 ++
SLC7A3 +
SLC12A5 -
SLC18A2 ++
SLC30A2 -
SLC24A2 +
Tubulins
TUBA1 -n . c .
TUBB +
Tissue Inhibitor of metalloproteinase
TIMP1 ++ T I M P 1 +
+, upregulated -, downregulated; n.c., not changed from control cultures; gene symbols are from IPA ToolBMC Genomics 2009, 10:90 http://www.biomedcentral.com/1471-2164/10/90
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reverse-transcribed using Superscript II Reverse Tran-
scriptase (GibcoBRL) according to the manufacturer's
instructions.
PCR reactions were performed in glass capillaries with the
LightCycler thermal cycler system (Software version 3.5;
Roche Diagnostics, Mannheim, Germany) using the
LightCycler DNA Master SYBR Green I kit (Roche Diag-
nostics, Mannheim) according to the manufacturer's
instructions. The primers used for RT-PCR analyses were
rat S12 forward: 5'-GGC ATA GCT GCT GGA GGT GTA A-
3'; rat S12 reverse: 5'-CCT TGG CCT GAG ATT CTT TGC-
3'; rat REG3B forward: 5'-GGT TTG ATG CAG AAC TGG
CCT-3'; rat REG3B reverse: 5'-TGA CAA GCT GCC ACA
GAA TCC-3'; rat GAP-43 forward: 5'-CGT TGC TGA TGG
TGT GGA GAA-3'; rat GAP-43 reverse: 5'-GCA GGC ACA
TCG GCT TGT TTA-3'. PCR conditions were: 50 cycles
with denaturation at 95°C for 8 seconds, annealing at
57°C for 8 seconds, and extension at 72°C for 14 seconds.
Negative controls without cDNA (non-template controls;
ntc) were run concomitantly. Specificity of amplified PCR
products was confirmed by melting curve analysis after
completion of the PCR run. Each PCR was performed in 3
independent experiments (n = 3) using different cell-cul-
ture batches.
Quantification of LightCycler qRT-PCR data
Quantification of data was performed with the LightCy-
cler software 3.3 (Roche Diagnostics) using the ΔΔCp
method. The difference between the crossing points (CPs;
ΔCp values) for the target mRNA samples and reference
S12 RNA samples (ΔΔCp) was used to calculate the expres-
sion values of the target mRNAs (2-Δ(ΔCp)).
Ingenuity global functional analyses
To investigate possible biological interactions of differ-
ently regulated genes, datasets representing genes with
altered expression profile derived from microarray analy-
ses were imported into the Ingenuity Pathway Analysis
Tool (IPA Tool; Ingenuity®Systems, Redwood City, CA,
USA; http://www.ingenuity.com). The basis of the IPA-
program consists of the Ingenuity Pathway Knowledge
Base (IPKB) which is derived from known functions and
interactions of genes published in the literature. Thus, the
IPA Tool allows the identification of biological networks,
global functions and functional pathways of a particular
dataset. The complete dataset containing gene identifiers
(Genbank accession numbers) and corresponding expres-
sion values was uploaded into the application. Each gene
identifier is mapped to its corresponding gene object in
the IPKB. Each gene product is assigned to functional (e.g.
"cellular growth and proliferation") and sub-functional
(e.g. "colony formation") categories. The biological func-
tions that are most significant to the dataset are identified
by the use of Fischer's exact test to calculate a p-value that
determines the probability that each biological function
assigned to that data set is due to chance alone.
Statistical analysis
Differences were tested by Welch's t-test based on three
independent experiments, and p-values less than 0.05
were considered statistically significant. Values are
expressed as means ± SEM.
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